Current stock page

Financial Data

TVTX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

TVTXTravere Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$50.65−$0.91 (−1.76%)

Latest quote

  • Momentum
    67
  • Value
    69
  • Quality
    63
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$224.56M$169.58M$127.2M$129.69M$164.86M$114.45M$81.73M$74.79M
Gross Profit$221.7M$167.41M$100.43M$127.14M$163.27M$112.93M$77.05M$72.23M
Operating Income-$68.11M$3.95M-$36.92M-$32.43M$24.93M-$12.65M-$42.67M-$60.74M
Net Income-$52.34M-$34.8M-$37.1M$2.73M$25.71M-$12.76M-$41.23M-$60.26M
EPS-$0.55-$0.37-$0.4-$0.24$0.29-$0.14-$0.47-$0.73
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$98.2M$58.07M-$40.37M$60.68M$14.32M$4.98M-$42.19M-$35.72M
Capital Expenditure$0$0-$22.18M-$18.86M-$140K-$235K-$11.78M-$9.56M
Free Cash Flow$98.2M$58.07M-$62.54M$41.81M$14.18M$4.75M-$53.98M-$45.28M
Net Cash Provided By Operating Activities$98.2M$58.07M-$40.37M$60.68M$14.32M$4.98M-$42.19M-$35.72M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$848.23M$799.36M$555.19M$605.19M$538.58M$555.31M$548.8M$594.13M
Total Debt$616.16M$616.91M$327.66M$339.87M$329.75M$399.57M$400.46M$401.58M
Cash And Cash Equivalents$123.54M$117.74M$78.36M$93.04M$110.93M$75.15M$61.9M$58.54M
Total Liabilities$825.65M$774.84M$456.46M$490.36M$465.02M$522.56M$515.98M$535.05M
Total Stockholders Equity$22.58M$24.52M$98.73M$114.83M$73.56M$32.75M$32.82M$59.08M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio204.77213.5541.7923.0441.3646.8355.8833.17
P/S ratio7.36———————
Debt To Equity27.2825.163.322.964.4812.212.26.8
Free Cash Flow Yield2.93%0.98%-0.04%0.26%-2.64%-9.47%-11.02%-13.97%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio204.77213.5541.7923.0441.3646.8355.8833.17
P/S ratio7.36———————
Return On Equity-5.38%-177.24%-21.70%-22.25%-120.36%-5.16%-6.91%-5.44%
Debt To Equity27.2825.163.322.964.4812.212.26.8

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-32.47x
Pb212.23x
Revenue Growth Yoy36.22%
EPS Growth Yoy-289.66%
Gross Margin94.72%
Operating Margin-20.50%
ROE-186.46%
ROIC-20.05%
Debt To Equity27.28
FCF Yield2.79%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$50.65
Volume708,198
RSI (14)43.94
MACD-1.09
MACD signal-1.57
MACD histogram0.48
ADX (14)16.21
SMA (50)$55.93
SMA (200)$47.68
ATR (14)$2.47
Historical volatility (annualized)44.82%
Volume (20-day average)2.24M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score55/100
Beta1.3
Annual volatility62.28%
Max Drawdown-33.49%
Sharpe Ratio0.87
VaR (95%, 1-day)-4.54%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

TVTX Financial Data FAQ

What is Travere Therapeutics, Inc.'s revenue?

Travere Therapeutics, Inc.'s revenue is one of the core financial data points for TVTX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Travere Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Travere Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is TVTX's EPS?

TVTX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Travere Therapeutics, Inc.'s net income?

Travere Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Travere Therapeutics, Inc. generate?

Free cash flow shows how much cash Travere Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Travere Therapeutics, Inc. have?

Cash and debt help frame TVTX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.